The standard adult AML dosing of 400 mg daily (or adult equivalent weight-based dosing), with a bioequivalent dose for patients receiving a concurrent CYP3A4 inhibitor, was given. The gene discussed is CYP3A4; the disease is acute myeloid leukemia.